Employers are urging Congress to take action on drug prices following the FDA’s recent approval of controversial Alzheimer’s disease drug Aduhelm. Aduhelm, or aducanumab, was developed by Biogen and Eisai and was approved by the Food and Drug Administration earlier this month despite pushback from the scientific community about the drug’s efficacy. Following its approval, Biogen said ...

Senate Majority Leader Charles Schumer (D-N.Y.) on Sunday threw his support behind a push, led by Sen. Bernie Sanders (I-Vt.), to add dental, vision and hearing coverage to Medicare. “There is a gaping hole in Medicare that leaves out dental, vision, and hearing coverage. This is a serious problem,” Schumer wrote on Twitter.

Over the next month, California Insurance Commissioner Ricardo Lara will review rates recommended by the Workers Compensation Insurance Rating Bureau, a nonprofit which evaluates trends, including the costs of potential claims.

In any other year, an employee would likely automatically renew benefits during their open enrollment period without a second thought. But the pandemic exposed flaws in open enrollment platforms and procedures throughout the country, and experts say long term changes are in the works for 2021 and beyond.

A new initiative aiming to create cheaper generic drugs for retail pharmacies signed on Anthem Blue Cross Blue Shield — one the largest insurers in the U.S. — as well as drug manufacturer Catalent as partners, officials announced this morning.

U.S. prescription drug spending will jump at least 8% by the mid-2020s as a controversial new Alzheimer’s disease drug hits the market, a new analysis finds.